News | Heart Failure | May 26, 2017

Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients

Three-year and 30-day outcomes from global MAVERIC clinical trial demonstrate utility of the system to treat functional mitral valve regurgitation

Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients

May 26, 2017 — Recent outcomes from the MAVERIC clinical trial confirm earlier positive findings that MVRx’s Arto System safely and effectively treats mitral valve regurgitation associated with congestive heart failure. The results, presented by leading cardiologists at EuroPCR 2017, May 16-19 in Paris, France, offer heart patients the promise of a less-invasive treatment for a life-threatening problem that affects more than 5 million people worldwide.

The ARTO System, a proprietary implantable device, is designed to improve heart failure symptoms by reducing mitral valve regurgitation, or the backward leakage of blood through the mitral valve, thereby increasing the forward flow of blood to the rest of the body. As a result, the heart functions more effectively and efficiently, leading to improved circulation, breathing and exercise tolerance.

The three-year Phase I portion of the MAVERIC study included 11 patients enrolled at Pauls Stradins University Clinical Hospital, Riga, Latvia. The results, presented by principal investigator Andrejs Erglis, M.D., Ph.D., demonstrate that the Arto System continues to provide a strong safety profile with 100 percent device success. Researchers found no instances of coronary artery compression, significantly reduced mitral valve regurgitation and significantly improved New York Heart Association (NYHA) heart function classification, a measure of heart failure. Moreover, heart-failure hospitalization fell 64 percent in the two years after Arto treatment compared with the two years prior. These results match those previously reported at earlier time points.

The current 30-day results from the multi-center MAVERIC trial were presented by Stephen Worthley, MB, BS, Ph.D., on behalf of the MAVERIC investigators. The report encompassed 45 patients inclusive of the 11 Phase I patients and represents a significant acceleration of enrollment beyond the single-center study. The 30-day results demonstrate that the Arto System is safe with 100 percent device success; there were no deaths, strokes or myocardial infarctions. At one month the findings also showed significantly reduced mitral valve regurgitation and significantly improved heart function. The 30-day results demonstrate that the safe and beneficial performance seen in the Phase I single-center study persists in a multi-center multi-operator setting.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init